| NCT ID | NCT07466784 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of British Columbia |
| Condition | Opioid Use Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 7,200 participants |
| Start Date | 2025-07-24 |
| Primary Completion | 2030-07-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 7,200 participants in total. It began in 2025-07-24 with a primary completion date of 2030-07-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Unregulated opioids remain a leading driver of preventable mortality and potential years of life lost in Canada. Emergency departments (EDs)-open 24/7 and frequently accessed by people who use drugs-offer critical opportunities to reverse toxicity, mitigate harm, and initiate treatment. Yet, high quality evidence to guide ED care for patients with opioid poisoning and concomitant opioid dependence or opioid use disorder is limited. The investigators aim to establish a pan Canadian registry of patients presenting to EDs with opioid poisoning to generate timely, practice informing evidence. The investigators will create the Canadian Emergency Department Research Network (CEDRN) Opioid Registry across participating EDs nationwide. Using automated screening of electronic health records (EHRs), the investigators will identify consecutive patients of all ages with suspected or confirmed opioid poisoning at their index ED visit. The project's objectives are to establish a pan-Canadian registry of Emergency Department patients presenting with opioid poisoning, harmonize data collection across participating sites, describe variations in patient characteristics, clinical practice and outcomes, and derive a clinical decision rule to predict the risk of dying within 60 days. The expected outcomes include advancing healthcare delivery, improving patient and provider experiences, and enhancing population health and health system sustainability for individuals with opioid poisoning. This research is crucial for addressing the opioid crisis in Canada and has the potential to significantly impact patient care and outcomes.
Eligibility Criteria
Inclusion Criteria: 1. All patients who arrive at the emergency department with the following emergency department discharge diagnosis: * Percocet Overdose * Oxycontin Overdose * Oxycodone Overdose * Opioid Overdose or Intoxication * Methadone Overdose * Heroin Overdose * Fentanyl Overdose * Codeine Overdose * Carfentanil Overdose * Opioid Withdrawal 2. All patients who arrive at the emergency department who had the following medication ordered in the present visit or previous hospital visits in the past 2 years: * Buprenorphine * Buprenorphine-naloxone * Methadone - Past ED or IP encounter * Kadian/Morphine long-acting * Naloxone * Naloxone kit 3. All patients who arrive at the emergency department with the following impatient discharge diagnosis: * Opioid use disorder (mild/moderate/severe, abuse/dependence), or opioid-related disorders * Adverse effect, and poisoning by polysubstance use * Opioid intoxication or withdrawal * Intoxication or withdrawal (from any substance, including unspecified ones) * Adverse effect, and poisoning by opioids, benzodiazepines, other antiepileptic and sedative-hypnotic drugs, and unspecified drugs * Any psychoactive substance abuse resulting in intoxication, withdrawal, or any adverse effects
Contact & Investigator
Corinne M Hohl, MD, MPH
PRINCIPAL INVESTIGATOR
University of British Columbia
Frequently Asked Questions
Who can join the NCT07466784 clinical trial?
This trial is open to participants of all sexes, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07466784 currently recruiting?
Yes, NCT07466784 is actively recruiting participants. Contact the research team at jeffrey.hau@ubc.ca for enrollment information.
Where is the NCT07466784 trial being conducted?
This trial is being conducted at Vancouver, Canada.
Who is sponsoring the NCT07466784 clinical trial?
NCT07466784 is sponsored by University of British Columbia. The principal investigator is Corinne M Hohl, MD, MPH at University of British Columbia. The trial plans to enroll 7,200 participants.